Antea Krsek

Mrs. Antea Krsek


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 December 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
TCTatjana Bogović Crnčić
Tatjana Bogović Crnčić
BĆBožena Ćurko-Cofek
Božena Ćurko-Cofek
LBLara Baticic
Lara Baticic
NGNEVA GIROTTO
NEVA GIROTTO
MTMaja Ilić Tomaš
Maja Ilić Tomaš
SKSanja Klobučar
Sanja Klobučar
Autoimmune thyroid disease (AITD) is the leading cause of thyroid dysfunction globally, characterized primarily by two distinct clinical manifestations: Hashimoto’s thyroiditis (HT) and Graves’ disease (GD). The prevalence of AITD is approximately twice as high in women compared to men, with a particularly pronounced risk during the reproductive years. Pregnancy exerts profound effects on thyroid physiology and immune regulation due to hormonal fluctuations and immune adaptations aimed at fostering maternal–fetal tolerance, potentially triggering or exacerbating AITD. The impact of AITD on pregnancy outcomes is multifaceted. Both HT and GD have been associated with adverse obstetric and neonatal outcomes, including miscarriage, preterm delivery, preeclampsia and fetal growth restriction. Inadequately managed AITD can also affect fetal neurodevelopment due to disrupted maternal thyroid hormone availability during critical periods of brain maturation. This review explores the complex interplay between the genetic, epigenetic and environmental factors that drive AITD during pregnancy, highlighting their roles in disease development and impacts on pregnancy outcomes. Gaining a deeper understanding of these mechanisms is crucial for improving diagnostic tools, treatment options and preventive measures to enhance the health and well-being of both the mother and the newborn.

24 August 2024 in Medicina
Verified
Journal Article
Open access
PDF file
AKAntea Krsek
Antea Krsek
AJAna Jagodic
Ana Jagodic
LBLara Baticic
Lara Baticic
Nanomedicine is a newer, promising approach to promote neuroprotection, neuroregeneration, and modulation of the blood–brain barrier. This review includes the integration of various nanomaterials in neurological disorders. In addition, gelatin-based hydrogels, which have huge potential due to biocompatibility, maintenance of porosity, and enhanced neural process outgrowth, are reviewed. Chemical modification of these hydrogels, especially with guanidine moieties, has shown improved neuron viability and underscores tailored biomaterial design in neural applications. This review further discusses strategies to modulate the blood–brain barrier—a factor critically associated with the effective delivery of drugs to the central nervous system. These advances bring supportive solutions to the solving of neurological conditions and innovative therapies for their treatment. Nanomedicine, as applied to neuroscience, presents a significant leap forward in new therapeutic strategies that might help raise the treatment and management of neurological disorders to much better levels. Our aim was to summarize the current state-of-knowledge in this field.

Verified
Journal Article
Open access
PDF file
AKAntea Krsek
Antea Krsek
LBLara Baticic
Lara Baticic
BĆBožena Ćurko-Cofek
Božena Ćurko-Cofek
TBTanja Batinac
Tanja Batinac
GLGordana Laškarin
Gordana Laškarin
VSVlatka Sotošek
Vlatka Sotošek
The endothelial glycocalyx (EGC) is a layer of proteoglycans (associated with glycosaminoglycans) and glycoproteins, which adsorbs plasma proteins on the luminal surface of endothelial cells. Its main function is to participate in separating the circulating blood from the inner layers of the vessels and the surrounding tissues. Physiologically, the EGC stimulates mechanotransduction, the endothelial charge, thrombocyte adhesion, leukocyte tissue recruitment, and molecule extravasation. Hence, severe impairment of the EGC has been implicated in various pathological conditions, including sepsis, diabetes, chronic kidney disease, inflammatory disorders, hypernatremia, hypervolemia, atherosclerosis, and ischemia/reperfusion injury. Moreover, alterations in EGC have been associated with altered responses to therapeutic interventions in conditions such as cardiovascular diseases. Investigation into the function of the glycocalyx has expanded knowledge about vascular disorders and indicated the need to consider new approaches in the treatment of severe endothelial dysfunction. This review aims to present the current understanding of the molecular mechanisms underlying cardiovascular diseases and to elucidate the impact of heart surgery on EGC dysfunction.

Verified
Journal Article
Open access
PDF file
AJAna Jagodić
Ana Jagodić
DZDorotea Zivalj
Dorotea Zivalj
AKAntea Krsek
Antea Krsek
LBLara Baticic
Lara Baticic
Ischemic stroke is a complex, multifactorial disorder with a significant heritable component. Recent developments in genome-wide association studies (GWASs) have identified several common variants associated with clinical outcomes, stroke subtypes, and overall risk. Key loci implicated in biological pathways related to vascular integrity, lipid metabolism, inflammation, and atherogenesis include 9p21 (ANRIL), HDAC9, SORT1, and PITX2. Although polygenic risk scores (PRSs) hold promise for early risk prediction and stratification, their clinical utility remains limited by Eurocentric bias and missing heritability. Integrating multiomics approaches, such as functional genomics, transcriptomics, and epigenomics, enhances our understanding of stroke pathophysiology and paves the way for precision medicine. This review summarizes the current genetic landscape of ischemic stroke, emphasizing how evolving methodologies are shaping its prevention, diagnosis, and treatment.

24 December 2025 in Gastrointestinal Disorders
Verified
Journal Article
Open access
PDF file
JFJan Finderle
Jan Finderle
VSValentin Silvano Schleicher
Valentin Silvano Schleicher
LSLou Marie Salomé Schleicher
Lou Marie Salomé Schleicher
AKAntea Krsek
Antea Krsek
TBTamara Braut
Tamara Braut
LBLara Baticic
Lara Baticic
The gut microbiota plays a fundamental role in human physiology by influencing metabolism, immunity, and neuroendocrine communication. Growing evidence suggests that physical exercise modulates gut microbial composition; however, study findings remain inconsistent due to variations in design, training type, and population characteristics. This review summarizes current research on how different forms, intensities, and frequencies of exercise shape the gut microbiota and discusses their implications for athlete health and performance. Moderate and sustained physical activity generally promotes higher microbial diversity, increases short-chain fatty acid (SCFA)-producing bacteria, and enhances gut barrier integrity. Endurance training, particularly long-term, is most consistently associated with beneficial microbial shifts, including increases in Prevotella, Akkermansia, and Faecalibacterium. In contrast, excessive or high-intensity endurance exercise was shown to cause dysbiosis, inflammation, and greater intestinal permeability. Resistance training appears to induce milder changes but was shown to improve mucin synthesis and butyrate production, especially in older adults. Exercise frequency also plays a role, with regular daily training enriching metabolic pathways linked to gut and systemic health. Overall, the impact of exercise on the gut microbiota depends on the type, intensity, and duration of activity. Balanced, moderate exercise combined with a healthy diet emerges as the most effective strategy to enhance microbial diversity, reduce inflammation, and support overall performance and well-being in athletes.

1 March 2026 in Life
Verified
Journal Article
Open access
PDF file
DZDorotea Zivalj
Dorotea Zivalj
LSLou Marie Salomé Schleicher
Lou Marie Salomé Schleicher
AKAntea Krsek
Antea Krsek
HDHadid Diamee
Hadid Diamee
DRDamir Raljevic
Damir Raljevic
LBLara Baticic
Lara Baticic
Heart failure (HF) remains a leading cause of morbidity and mortality worldwide and is driven by complex, interconnected pathophysiological processes, including maladaptive cardiac remodeling, fibrosis, hypertrophy, metabolic dysregulation, and cardiomyocyte loss. MicroRNAs (miRNAs), small non-coding RNAs that act as key post-transcriptional regulators of gene expression, have emerged as important coordinators of these processes across cardiomyocytes and non-myocyte cardiac cell populations. In addition to altered expression patterns, accumulating evidence indicates that miRNA activity is dynamically influenced by regulated biogenesis, maturation, and context-dependent mechanisms of action. Through reversible translational repression and longer-term mRNA destabilization, miRNAs support adaptive responses to acute cardiac stress, whereas their persistent dysregulation contributes to remodeling pathways that promote HF progression. This comprehensive narrative review provides an integrative overview of current knowledge on the role of miRNA networks in shaping the molecular heterogeneity of heart failure across disease stages, phenotypes, and cardiac cell types. Drawing on a broad body of experimental and clinical literature, we discuss advances in understanding miRNA biogenesis, post-transcriptional control, and cell-specific effects, while highlighting conceptual developments rather than applying systematic selection criteria. We further examine the translational and clinical implications of miRNA biology, critically considering the progress of miRNA-based therapeutics alongside the biological and practical challenges that continue to limit their widespread clinical implementation. In parallel, we explore the emerging potential of circulating miRNAs as minimally invasive biomarkers that reflect upstream regulatory stress at the level of RNA processing and post-transcriptional regulation. Finally, we address the growing application of artificial intelligence and machine learning approaches to high-dimensional miRNA datasets, which enable integrative analyses across clinical, imaging, and multi-omics domains and support biomarker discovery, patient stratification, and prediction of therapeutic response. Collectively, miRNA biology, supported by systems-level and AI-driven analytical frameworks, offers a unifying perspective for understanding, classifying, and monitoring cardiac remodeling in heart failure.